Eisai 2013 Forerunner Sales Flat, But Generics Up 19.3% To ¥23.4 Billion
This article was originally published in PharmAsia News
Executive Summary
Eisai’s forerunner drug sales in Japan remained flat in 2013, according to the latest financial results announcement from the company, but sales of generics rose smartly.